Found: 16
Select item for more details and to access through your institution.
PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance.
- Published in:
- Nature Communications, 2020, v. 11, n. 1, p. 1, doi. 10.1038/s41467-020-17697-1
- By:
- Publication type:
- Article
Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00483-1
- By:
- Publication type:
- Article
Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Identification of chemokine receptors as potential modulators of endocrine resistance in estrogen receptor positive breast cancers.
- Published in:
- Breast Cancer Research, 2014, v. 16, n. 5, p. 1, doi. 10.1186/s13058-014-0447-1
- By:
- Publication type:
- Article
Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor-positive breast cancers.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo.
- Published in:
- Breast Cancer Research, 2012, v. 14, n. 5, p. 3330, doi. 10.1186/bcr3330
- By:
- Publication type:
- Article
Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Abiraterone shows alternate activity in models of endocrine resistant and sensitive disease.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance.
- Published in:
- Nature Communications, 2017, v. 8, n. 1, p. 1, doi. 10.1038/s41467-017-01864-y
- By:
- Publication type:
- Article
ESR1 Is Co-Expressed with Closely Adjacent Uncharacterised Genes Spanning a Breast Cancer Susceptibility Locus at 6q25.1.
- Published in:
- PLoS Genetics, 2011, v. 7, n. 4, p. 1, doi. 10.1371/journal.pgen.1001382
- By:
- Publication type:
- Article
Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer.
- Published in:
- 2020
- By:
- Publication type:
- corrected article
Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Amino acid depletion modulates vascular endothelial growth factor production during the life span of human vascular smooth muscle cells.
- Published in:
- Journal of Cellular Physiology, 1998, v. 176, n. 2, p. 359, doi. 10.1002/(SICI)1097-4652(199808)176:2<359::AID-JCP14>3.0.CO;2-Z
- By:
- Publication type:
- Article
Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
- Published in:
- PLoS ONE, 2016, v. 11, n. 6, p. 1, doi. 10.1371/journal.pone.0157397
- By:
- Publication type:
- Article